Detalhe da pesquisa
1.
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
Nature
; 623(7985): 157-166, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37853118
2.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med
; 389(7): 589-601, 2023 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272516
3.
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
Nature
; 565(7738): 234-239, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568305
4.
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
Lancet Oncol
; 25(1): e29-e41, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38181810
5.
Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Curr Neurol Neurosci Rep
; 24(2): 17-25, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38170429
6.
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.
Lancet Oncol
; 24(4): e161-e171, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990614
7.
Novel trial designs in neuro-oncology.
Curr Opin Neurol
; 36(6): 571-578, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37865854
8.
Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
J Neurooncol
; 165(1): 101-112, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864646
9.
Molecular Profiling and Targeted Therapies in Gliomas.
Curr Neurol Neurosci Rep
; 23(10): 627-636, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37812369
10.
Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities.
Lancet Oncol
; 23(2): e62-e74, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35114133
11.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol
; 23(1): 53-64, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838156
12.
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
J Neurooncol
; 158(1): 111-116, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35474499
13.
DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.
J Neurooncol
; 157(3): 499-510, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384518
14.
Leveraging external data in the design and analysis of clinical trials in neuro-oncology.
Lancet Oncol
; 22(10): e456-e465, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34592195
15.
IDH-mutant gliomas with additional class-defining molecular events.
Mod Pathol
; 34(7): 1236-1244, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33772213
16.
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.
J Neurooncol
; 152(3): 515-522, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33646525
17.
Medical and Neurological Management of Brain Tumor Complications.
Curr Neurol Neurosci Rep
; 21(10): 53, 2021 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34545509
18.
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Lancet Oncol
; 21(9): 1234-1243, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818466
19.
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Lancet Oncol
; 21(6): e317-e329, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502458
20.
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Lancet Oncol
; 21(2): e97-e103, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32007210